Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer

Summary

Multicenter, prospective, open-labeled, 2-arm, randomized non-comparative (2:1) phase II trial assessing the efficacy of lurbinectedin in association with durvalumab

Timeline

Start

2023-10

Primary completion

2024-05-31

Completion

2024-05-31

Outcome

Outcome not reported

Stopped (Enrollment): “Recruitment difficulties, decline in the incidence of the studied pathology, active competitive clinical trials”

Drugs

Indications